search

Active clinical trials for "Carcinoma, Renal Cell"

Results 361-370 of 1644

Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors

Kidney NeoplasmRenal Cancer1 more

Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative to surgery to control localized primary renal cancer cell (RCC) in medically inoperable patients. Although large prospective studies are lacking, we report our institutional database of primary RCC treated with SBRT.

Recruiting11 enrollment criteria

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

CarcinomaRenal Cell Carcinoma3 more

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

Recruiting12 enrollment criteria

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma...

Non Clear Cell Renal Carcinoma

The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer. The goal of this study was to evaluate the efficacy and safety of sintilimab (a human programmed death-1 ICI) plus anlotinib (a multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signaling) in advanced non clear cell renal cell carcinoma.

Not yet recruiting34 enrollment criteria

Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients

Cancer of Kidney

Among patients with renal cell carcinoma (RCC), 2.7 to 4.7 % of patients are at risk of progressing to dialysis or transplantation after partial and radical nephrectomy respectively. Of note, similar risk factors can be seen in both disease: RCC and renal impairment leading to dialysis. Currently, three types of systemic therapies (ST) are mainly used among patients with metastatic renal cell carcinoma (mRCC): anti-angiogenics (mostly tyrosine kinase inhibitors and bevacizumab), mTOR inhibitors and immune checkpoint inhibitor. ST prescription for patients undergoing HD may be more dangerous than in other patients. This is partially explained by the fact that several adverse events can be induced by both the ST and HD e.g. thromboembolic disease, or hypertension. Patients in HD are usually excluded from major clinical trials and available data concerning safety and activity of ST in this specific population are lacking. In most cases, drugs' label is driven by the eligibility criteria of large randomized phase 3 trials that exclude this type of patients. The main source of information for these patients comes from academic publications of patients' cases or small cohorts, but they are not included within the drug label. Moreover, no clear guidelines are given by savant societies regarding those patients. It is known that patients with HD are at high risk of specific adverse events that can sometimes overlap with the safety profile of anti-cancer drugs: thromboembolic complications, cardio-vascular comorbidities, hematologic and metabolic abnormalities. Having a dedicated clinical trial to this particular population would definitely help the community to improve the care of HD patients by getting prospective data in order to increase the level of evidence and therefore to optimize anticancer drug use in this specific population.

Not yet recruiting24 enrollment criteria

Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

Bladder CancerRenal Cancer

Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells

Not yet recruiting7 enrollment criteria

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid...

Advanced Malignant Solid NeoplasmBladder Carcinoma48 more

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Active102 enrollment criteria

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry...

CancerMetastatic45 more

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Recruiting7 enrollment criteria

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With...

Renal Cancer

Usually, doctors monitor kidney cancer with CT scans to measure the size of tumors. Sometimes, even when a drug is working, it can take several months before the effects are seen on a regular CT scan. The purpose of this study is to see if a new kind of scan, called 124I-cG250 PET/CT, can determine response to sunitinib or pazopanib earlier than a regular CT scan. Research has shown that certain proteins in the blood, called antibodies, can attach themselves to cancer cells without binding to normal cells. In this study, an antibody is used called chimeric G250 (cG250) that is attached to a radioactive isotope. The radioactive isotope in this study is Iodine-124 (124I). If cG250 has attached to tumors in the body, 124I shows up on the PET scan.

Active24 enrollment criteria

Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms...

Liver CancerLiver Metastasis Colon Cancer2 more

The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies. The main question it aims to evaluate the short, medium and long-term clinical course of patients treated with MWA. Participants will not alter their normal clinical and therapeutic practice, due to the observational nature of the study, and all data regarding microwave treatments will be collected (including demographic data). follow their normal clinical and therapeutic path

Recruiting7 enrollment criteria

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced...

Advanced or Metastatic Renal Cell Carcinoma

The purpose of the protocol, is to describe the use of CabometyxTM (cabozantinib) tablets as monotherapy or in combination with nivolumab including the number of dose reductions, dose interruptions and terminations due to (serious) adverse events in subjects with advanced or metastatic renal cell carcinoma (mRCC) treated in real-life clinical setting in 1st line treatment.

Recruiting6 enrollment criteria
1...363738...165

Need Help? Contact our team!


We'll reach out to this number within 24 hrs